Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798054 | 0.80 | PNP (0.39) | FDPSLMNAADRB3PDE4DPDE3A | |
| SCHEMBL8050312 | 0.78 | FDPS (0.54) | FDPSLMNAADRB3PDE4DPDE3A | |
| SCHEMBL267914 | 0.77 | LPAR3 (0.37) | FDPSLPAR1LPAR3PPARDTSHR | |
| SCHEMBL8049638 | 0.76 | FDPS (0.61) | FDPSLMNAADRB3PDE4DPDE3A | |
| SCHEMBL15022840 | 0.75 | LPAR1 (0.33) | LPAR1LPAR3PPARDTSHR | |
| SCHEMBL10128514 | 0.73 | TSHR (0.42) | LPAR1LPAR3PPARDTSHRGRM4 | |
| SCHEMBL15022714 | 0.72 | FDPS (0.54) | FDPSLMNAADRB3PDE4DPDE3A | |
| SCHEMBL3502263 | 0.71 | TSHR (0.40) | LMNALPAR1LPAR3PPARDTSHR | |
| SCHEMBL10128548 | 0.69 | PPARD (0.39) | LPAR1LPAR3PPARDTSHRGRM4 | |
| SCHEMBL11693393 | 0.69 | TSHR (0.48) | LPAR1LPAR3PPARDTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140171393-A1 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171393-A1 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171393-A1 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | FDPS 832/4885LMNA 4755/4885ADRB3 13/4885 |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | FDPS 1935/4885LMNA 3781/4885ADRB3 43/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | FDPS 1935/4885LMNA 3781/4885ADRB3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.